Download full-text

Full-text

Available from: Amir Farshchi, Jul 29, 2015
3 Followers
 · 
358 Views
  • Source
    • "Drugs such as antibiotics that were thought to be useful in short-term treatment are newly applied for chronic illnesses such as inflammatory bowel disease or irritable bowel syndrome [21] [22] [23] [24]. Thus, apart from volume of drug treatments that is increasing day to day, their value is also growing [20] [25] [26], and all these have highlighted the importance of accurate models for analysing and making decision on economics aspects, and considering opportunity costs. On the other hand, very close effectiveness of such medicine to placebo or even their ineffectiveness necessitates clarification by meta-analyses [27] [28] [29] [30]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tolerability is an essential part of drug therapy and can affect health and economic outcomes. Withdrawal due to adverse reactions of medicines or lack of effectiveness is a major concern in long-term treatments that influences cost-effectiveness analysis. In case of possibility of stopping and switch to other interventions in decision analysis model, overhead costing may affect results and decision-making processes. Thus, modifying of classic decision analysis model seems to be necessary in such cases. My hypothesis is that by the use of a new decision model that can make links between different Markov-like models accurate cost calculation could be achieved. The appearance of model is going to be like a semicycle net. Considering the probability of switching from one treatment strategy to another, one could give more precise economic evaluation results. In the first step, this model needs to be tested and compared with the conventional model. In the second step, the impact of these differences has to be examined in the practical field of health, drug policy and supply management. By applying this new decision model in total health budget, threshold and its consequences on national health accounts and share of health in gross domestic product should be tested.
    Iranian Journal of Medical Hypotheses and Ideas 01/2012; 6(1):12–15. DOI:10.1016/j.jmhi.2012.03.008
  • Source
    06/2011; 7(3):365-7. DOI:10.5114/aoms.2011.23397
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the prescribing and usage pattern of all dosage forms of tramadol and to assess the type and frequency of tramadol-induced adverse drug reactions. All insured prescriptions which were collected in special software called Rx Analyst in the National Committee of Rational Drug Use were reviewed for prescriptions included at least one dosage form of tramadol. Data related to dispensing of tramadol were obtained from the official databank of national regulatory authority. All registered tramadol forms that induced adverse drug reactions in the database of Iranian Adverse Drug Reaction Monitoring Center were analyzed. The study period for all mentioned data was defined from 2006 to 2010. There were 291, 940 dosage forms of tramadol in 336, 610, 664 insured prescriptions in comparison to 1, 474, 680, 760 number of all dosage forms which dispensed from wholesaler to retail pharmacies during five years in the study. There were 461 different adverse reactions occurred in 249 patients. The most reported reactions included convulsion (73 items), nausea (56 items) and vomiting (47 items). We detected three death suspected to be induced by tramadol. Assessment of the trend of adverse reactions showed that the total number of reports was reduced from 89 cases in 2006 to 21 in 2010. There is a gap between number of tramadol prescribed and dispensed in the country that may be related to self-medication of this medicine. This has important value for priority setting in implementing interventions for promoting rational use of tramadol.
    International Journal of Pharmacology 07/2011; 7(7):757-760. DOI:10.3923/ijp.2011.757.760 · 0.98 Impact Factor
Show more